Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
Rhea-AI Summary
Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharma focused on cystic fibrosis, will participate in two June 2026 investor conferences.
Management presents at the Jefferies Global Healthcare Conference on June 3, 2026, at 12:15 p.m. ET and a Goldman Sachs Global Healthcare fireside chat on June 10, 2026, at 10:00 a.m. ET. Live webcasts and replays will be available in the company’s Investors section online.
Positive
- None.
Negative
- None.
News Market Reaction – SION
In the May 27 session, SION gained 1.28%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Investor conference participation | Neutral | +5.3% | Announced participation in 2026 RBC Capital Markets healthcare conference. |
| May 12 | Quarterly earnings update | Negative | -10.9% | Reported Q1 2026 results with higher R&D, G&A and net loss. |
| Apr 27 | Clinical trial milestone | Positive | +2.9% | Completed enrollment in PreciSION CF Phase 2a trial of SION-719. |
| Apr 07 | Investor meetings announcement | Neutral | -1.7% | Planned one-on-one investor meetings at Raymond James biotech symposium. |
| Mar 02 | Earnings and pipeline update | Negative | -7.2% | Reported Q4/FY 2025 results with higher net loss and expenses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Price reactions have generally aligned with the tone of news: positive clinical updates saw gains, while earnings and higher losses coincided with declines. Conference participation has produced mixed but modest moves.
Over the last six months, Sionna has alternated between clinical and financial updates. Completion of enrollment in the PreciSION CF Phase 2a trial on Apr 27, 2026 saw a positive move, while Q1 2026 and FY 2025 earnings on May 12, 2026 and Mar 2, 2026 corresponded with declines amid wider losses. Several prior conference participation announcements in April–May 2026 produced relatively modest reactions, framing today’s June 2026 investor conference news as part of an ongoing investor outreach cadence.
Key Terms
cystic fibrosis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:
- 2026 Jefferies Global Healthcare Conference presentation on Wednesday, June 3rd, 2026, at 12:15 p.m. ET; and
- Goldman Sachs 47th Annual Global Healthcare Conference 2026 fireside chat on Wednesday, June 10th, 2026, at 10:00 a.m. ET
Live webcasts can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com. Replays will also be available following the events.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Sarah Spencer
media@sionnatx.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
